Andrea Arfé

ORCID: 0000-0003-1534-0609
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Statistical Methods in Clinical Trials
  • Health Systems, Economic Evaluations, Quality of Life
  • Statistical Methods and Inference
  • Cancer Genomics and Diagnostics
  • Inflammatory mediators and NSAID effects
  • Advanced Causal Inference Techniques
  • Bayesian Methods and Mixture Models
  • Breast Cancer Treatment Studies
  • Pharmaceutical studies and practices
  • Drug-Induced Adverse Reactions
  • Breast Lesions and Carcinomas
  • Asthma and respiratory diseases
  • Cancer Risks and Factors
  • Prostate Cancer Treatment and Research
  • Chronic Obstructive Pulmonary Disease (COPD) Research
  • Inhalation and Respiratory Drug Delivery
  • Pancreatic and Hepatic Oncology Research
  • Neuroendocrine Tumor Research Advances
  • Cancer Immunotherapy and Biomarkers
  • Antiplatelet Therapy and Cardiovascular Diseases
  • Optimal Experimental Design Methods
  • Biomedical Text Mining and Ontologies
  • Lung Cancer Treatments and Mutations
  • Global Cancer Incidence and Screening
  • Colorectal Cancer Screening and Detection

Memorial Sloan Kettering Cancer Center
2022-2024

University of Milano-Bicocca
2013-2022

Harvard University
2018-2021

Dana-Farber Cancer Institute
2018-2021

Bocconi University
2018-2020

Harvard University Press
2019

Duke University Hospital
2019

Duke Medical Center
2019

Massachusetts General Hospital
2019

Center of Immunology Pierre Fabre
2017

<b>Objectives</b>&nbsp;To investigate the cardiovascular safety of non-steroidal anti-inflammatory drugs (NSAIDs) and estimate risk hospital admission for heart failure with use individual NSAIDs. <b>Design</b>&nbsp;Nested case-control study. <b>Setting</b>&nbsp;Five population based healthcare databases from four European countries (the Netherlands, Italy, Germany, United Kingdom). <b>Participants</b>&nbsp;Adult individuals (age ≥18 years) who started NSAID treatment in 2000-10. Overall, 92...

10.1136/bmj.i4857 article EN cc-by-nc BMJ 2016-09-28

Deviations from proportional hazards (DPHs), which may be more prevalent in the era of precision medicine and immunotherapy, can lead to underpowered trials or misleading conclusions. We used a meta-analytic approach estimate DPHs across cancer trials, investigate associated factors, evaluate data-analysis approaches for future trials.Experimental Design: searched PubMed phase III breast, lung, prostate, colorectal published preselected list journals between 2014 2016 extracted individual...

10.1158/1078-0432.ccr-18-3999 article EN Clinical Cancer Research 2019-07-25

Background Use of selective COX-2 non-steroidal anti-inflammatory drugs (NSAIDs) (coxibs) has been associated with an increased risk acute myocardial infarction (AMI). However, the AMI only studied for very few NSAIDs that are frequently used. Objectives To estimate individual NSAIDs. Methods A nested case-control study was performed from a cohort new NSAID users ≥18 years (1999–2011) matching cases to maximum 100 controls on database, sex, age, and calendar time. Data were retrieved six...

10.1371/journal.pone.0204746 article EN cc-by PLoS ONE 2018-11-01

Abstract Background: While the prognostic significance of pathological complete response (pCR) after neoadjuvant chemotherapy is relatively well established, impact adjuvant therapy in modulating relationship between pCR and long term outcomes less clear. The primary objective this study was to conduct a systematic review published studies comprehensively evaluate association with subsequent breast cancer recurrence mortality, stratified by subtypes usage. Methods: Based on PRISMA...

10.1158/1538-7445.sabcs18-gs2-03 article EN Cancer Research 2019-02-15

Background and purpose A multi-country European study using data from six healthcare databases four countries was performed to evaluate in a large population (>32 million) the risk of ischemic stroke (IS) associated with individual NSAIDs assess impact factors IS co-medication. Methods Case-control nested cohort new NSAID users. For each case, up 100 sex- age-matched controls were selected confounder-adjusted odds ratios for current use compared past calculated. Results 49,170 cases observed...

10.1371/journal.pone.0203362 article EN cc-by PLoS ONE 2018-09-19

Abstract Background Data on utilization patterns and safety of non-steroidal anti-inflammatory drugs (NSAIDs) in children are scarce. The purpose this study was to investigate the NSAIDs among four European countries as part Safety Of non-Steroidal (SOS) project. Methods We used longitudinal patient data from seven databases (GePaRD, IPCI, OSSIFF, Pedianet, PHARMO, SISR, THIN) calculate prevalence rates NSAID use (0–18 years age) Germany, Italy, Netherlands, United Kingdom. All contained a...

10.1186/1471-2431-13-192 article EN cc-by BMC Pediatrics 2013-11-19

Objectives To develop and validate a new algorithm to identify patients with rheumatoid arthritis (RA) estimate disease prevalence using administrative health databases (AHDs) of the Italian Lombardy region. Design Case–control cohort diagnostic accuracy study. Methods In randomly selected sample 827 drawn from tertiary rheumatology centre (training set), clinically validated diagnoses were linked data including codes drug prescriptions. An in steps decreasing specificity was developed its...

10.1136/bmjopen-2014-006029 article EN cc-by-nc BMJ Open 2015-01-01

To provide an updated review of cancer mortality trends in Italy, and census data, from 1970 to 2007, were extracted the WHO database analyzed using age-specific standardized rates, joinpoint regression. Total rates men have been declining by 1.8% yearly since 1994, reaching a rate 147 per 100 000 residents (world standard) 2007. In women, total decreasing 1.1% 1991, resulting 85 Avoided deaths, compared with 1988, lung, intestinal, stomach, breast cancers amount 30 646. men, driven lung...

10.1097/cej.0b013e328345f99e article EN European Journal of Cancer Prevention 2011-04-14

PURPOSE The molecular drivers underlying mucinous tumor pathogenicity are poorly understood. GNAS mutations predict metastatic burden and treatment resistance in appendiceal adenocarcinoma. We investigated the pan-cancer clinicopathologic relevance of variants. METHODS assessed 58,043 patients with Memorial Sloan Kettering-Integrated Mutation Profiling Actionable Cancer Targets (IMPACT)–sequenced solid tumors to identify oncogenic variants, including , associated phenotype. then performed...

10.1200/jco.24.00186 article EN Journal of Clinical Oncology 2024-08-09

Abstract Background and objective Real‐world evidence suggests that persistence with inhaled corticosteroids (ICS), the mainstay of asthma drug therapy, is generally poor. The effect ICS on risk exacerbation was addressed in a population‐based study. Methods cohort 2335 beneficiaries National Health Service provided by Italian Region Lombardy, aged 18–40 years newly treated during 2005–2008, followed from their first dispensation until 2010. Discontinuation treatment starting oral...

10.1111/resp.12791 article EN Respirology 2016-04-07

Programmed cell death receptor ligand 1 (PD-L1) expression is the most studied biomarker to predict efficacy of immune checkpoint inhibitors (ICIs), but its clinical significance controversial. We estimated distribution PD-L1 scores (ie, tumor proportion score or combined score) and relationship between levels ICIs' impact on overall survival (OS).We reconstructed, pooled, analyzed individual-level data 7,617 patients with cancer from 14 randomized trials. The effects ICIs were quantified...

10.1200/po.20.00150 article EN JCO Precision Oncology 2020-10-05

Guidelines for management of cardiovascular diseases stratify absolute risk into categories with a high-risk threshold defined at 20% events in 10 years, but it is unclear whether only major or the Framingham-extended definition should be considered. The 2013 ESH-ESC hypertension guidelines, instead, define as death SCORE model, setting high 5% level. It would therefore convenient to know quantitative relationship between risks different outcomes adopted by especially because some outcome...

10.1097/hjh.0000000000000077 article EN Journal of Hypertension 2013-12-30

We describe the long-term (1981–2008) dynamics of several physico-chemical and biological variables how their changes may have influenced zooplankton structure in Lake Maggiore (Italy). Data was available for 1981–1992 1995–2008 periods. Standardized time-series temperature total phosphorus (TP), chlorophyll-a, phytoplankton density (cel m−3), cell size (µm3), as well (Copepoda, Cladocera, Rotifera density, ind m−3) were smoothed using penalized B-splines analyzed Functional Principal...

10.3390/w11050962 article EN Water 2019-05-08

Healthcare utilization data are increasingly used for chronic disease surveillance. Nevertheless, no standard criteria estimating prevalence of high-impact diseases, such as obstructive pulmonary (COPD) and asthma, available. In this study an algorithm recognizing COPD/asthma cases from HCU is developed implemented in the databases Italian Lombardy Region (about 10 million residents). The impact diagnostic misclassification reliably was also assessed. Disease-specificdrug codes, hospital...

10.1186/s12890-016-0362-6 article EN cc-by BMC Pulmonary Medicine 2017-01-19

Incidence, predictors and effect of discontinuation long-acting bronchodilators on the risk death or hospital admission among adults with Chronic Obstructive Pulmonary Disease (COPD) were assessed in a large population-based prospective study carried out by linking Italian healthcare utilization databases. Specifically, cohort 17,490 beneficiaries National Health Service Region Lombardy, aged 40 years older, who started therapy during 2005–2008 was followed from first dispensation until...

10.3109/15412555.2016.1141877 article EN COPD Journal of Chronic Obstructive Pulmonary Disease 2016-03-02

Abstract Background Many new molecular entities enter clinical development to evaluate potential therapeutic benefits for oncology patients. We characterized adult and pediatric of the set that started testing in 2010-2015 worldwide. Methods extracted data from AdisInsight, an extensive database global pharmaceutical development, FDA.gov website. followed cohort initiating first-in-human phase I trials end 2020. For each entity, we determined whether it was granted US Food Drug...

10.1093/jnci/djad082 article EN JNCI Journal of the National Cancer Institute 2023-05-12

The use of simulation-based sensitivity analyses is fundamental for evaluating and comparing candidate designs future clinical trials. In this context, are especially useful to assess the dependence important design operating characteristics with respect various unknown parameters. Typical examples include likelihood detecting treatment effects average study duration, which depend on parameters that until after onset study, such as distributions primary outcomes patient profiles. Two crucial...

10.1080/00031305.2023.2216253 article EN The American Statistician 2023-05-24
Coming Soon ...